Log in
Enquire now
‌

US Patent 11286289 T cell receptors

Patent 11286289 was granted and assigned to Adaptimmune on March, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Adaptimmune
Adaptimmune
Current Assignee
Adaptimmune
Adaptimmune
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11286289
Date of Patent
March 29, 2022
Patent Application Number
16154192
Date Filed
October 8, 2018
Patent Citations
‌
US Patent 10117918 Antigen-specific T cell receptors and T cell epitopes
Patent Citations Received
‌
US Patent 11572400 T cell receptors
Patent Primary Examiner
‌
Sharon X Wen
CPC Code
‌
A61K 35/17
‌
C07K 14/4748
‌
C07K 14/7051
‌
G01N 33/53
‌
A61P 35/00

The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11286289 T cell receptors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.